(UroToday.com) In a session at the American Society for Radiation Oncology (ASTRO) Annual Congress focused on the care of patients with intermediate and high-risk prostate cancer, Dr. Kwok presented results of a prospective trial of aggressive therapy consisting of neoadjuvant chemotherapy and androgen deprivation therapy (ADT) followed by prostatectomy and adjuvant radiotherapy for patients with high and very-high risk prostate cancer.